2 Under-the-Radar Stocks That Could Soar

Terns Pharmaceuticals does have other pipeline candidates. It is developing TERN-501 as a potential medicine for metabolic dysfunction-associated steatohepatitis and as a potential combination therapy that could enhance the efficacy of GLP-1 medicines. Terns Pharmaceuticals' TERN-701 is a potential cancer therapy in a phase 1 study, with an upcoming data readout scheduled for the fourth quarter.With oral medications, drugmakers will have the opportunity to ramp up manufacturing and target even more patients ...